Evaluation of Apligraf® persistence and basement membrane restoration in donor site wounds: a pilot study

Apligraf® is a bilayered tissue‐engineered product consisting of a bovine collagen matrix with neonatal fibroblasts, overlaid by a stratified epithelium containing living keratinocytes. The United States Food and Drug Administration has approved its use for venous leg ulcers and neuropathic diabetic foot ulcers. Apligraf® provides a dermal matrix and produces cytokines similar to the human skin. However, its mechanism of action and ultimate fate in host wounds are unclear. The aim of this study was to evaluate the persistence of Apligraf® fibroblasts and keratinocytes in human acute partial‐thickness wounds (split‐thickness donor sites) treated with Apligraf®. In an open‐label, within‐patient, three‐centered, controlled pilot study, 10 patients were treated with Apligraf®, Apligraf® dermis only (without epidermis), and a polyurethane film for donor site wounds of the same size, depth, and anatomical location. Apligraf® DNA persistence was the primary outcome measure. Basement membrane components, cosmetic outcome, time to wound healing, and safety parameters were secondary outcome measures. One week after the initial treatment, reverse transcription polymerase chain reaction analysis found that two Apligraf® and two Apligraf® dermis‐only‐treated sites had Apligraf® DNA present. Four weeks posttreatment, only one Apligraf® and one Apligraf® dermis‐only sites showed the presence of Apligraf® DNA. There was no difference between the three treatment modalities in establishing basement membrane in donor site wounds. No differences in other secondary outcomes were found. Apligraf® DNA persisted in a minority of patients at 4 weeks in acute partial‐thickness wounds. Apligraf®'s success in speeding healing of acute wounds appears to be related to factors other than the persistence of donor DNA or effect on basement membrane restoration.

[1]  M. Auletta,et al.  Acute excisional wounds treated with a tissue-engineered skin (Apligraf). , 1999, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[2]  R. Kirsner,et al.  Techniques of split-thickness skin grafting for lower extremity ulcerations. , 1993, The Journal of dermatologic surgery and oncology.

[3]  S. Tyring,et al.  Natural killer cell activity is reduced in patients with severe forms of inherited epidermolysis bullosa. , 1989, Archives of dermatology.

[4]  D. Fivenson,et al.  Graftskin therapy in epidermolysis bullosa. , 2003, Journal of the American Academy of Dermatology.

[5]  C. H. Wyatt,et al.  Novel treatment strategy for leg and sternal wound complications after coronary artery bypass graft surgery: bioengineered Apligraf. , 2004, Annals of Thoracic Surgery.

[6]  R. Kirsner,et al.  Epidermolysis bullosa: identification and treatment. , 2003, Advances in skin & wound care.

[7]  V. Falanga,et al.  Human chronic wounds treated with bioengineered skin: histologic evidence of host-graft interactions. , 2002, Journal of the American Academy of Dermatology.

[8]  M. Sabolinski,et al.  The effect of a tissue engineered bilayered living skin analog, over meshed split-thickness autografts on the healing of excised burn wounds. The Apligraf Burn Study Group. , 2000, Burns : journal of the International Society for Burn Injuries.

[9]  O. Olerup,et al.  HLA‐DQB1 and ‐DQA1 typing by PCR amplification with sequence‐specific primers (PCR‐SSP) in 2 hours , 1993 .

[10]  V. Falanga,et al.  The longevity of a bilayered skin substitute after application to venous ulcers. , 2002, Archives of dermatology.

[11]  W. Eaglstein,et al.  A Composite Skin Substitute (Graftskin) for Surgical Wounds: A Clinical Experience , 1995, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[12]  V. Theobald,et al.  “NEUTRAL ALLOGRAFTS”‐LACK OF ALLOGENEIC STIMULATION BY CULTURED HUMAN CELLS EXPRESSING MHC CLASS I AND CLASS II ANTIGENS , 1993, Transplantation.

[13]  C. McCollum,et al.  Venous ulcer fibroblasts compared with normal fibroblasts show differences in collagen but not fibronectin production under both normal and hypoxic conditions. , 1996, The Journal of investigative dermatology.

[14]  V. Falanga,et al.  Accelerated healing of pyoderma gangrenosum treated with bioengineered skin and concomitant immunosuppression. , 2001, Journal of the American Academy of Dermatology.

[15]  Peter Shaw,et al.  The allogeneic response to cultured human skin equivalent in the hu-PBL-SCID mouse model of skin rejection. , 1999, Transplantation.

[16]  M. Auletta,et al.  Cultured skin as a 'smart material' for healing wounds: experience in venous ulcers. , 1996, Biomaterials.

[17]  David G Armstrong,et al.  Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. , 2001, Diabetes care.

[18]  W. A. Horn Graftskin heals an ulcer on an amputation stump. , 2000, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[19]  A. Falabella,et al.  Tissue-engineered skin (Apligraf) in the healing of patients with epidermolysis bullosa wounds. , 2000, Archives of dermatology.

[20]  R. Kirsner,et al.  Behavior of tissue-engineered skin: a comparison of a living skin equivalent, autograft, and occlusive dressing in human donor sites. , 1999, Archives of dermatology.

[21]  H. Brem,et al.  Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. , 2000, Archives of surgery.

[22]  C. Osborne,et al.  Epidermal–dermal interactions regulate gelatinase activity in Apligraf®, a tissue‐engineered human skin equivalent , 2002, The British journal of dermatology.

[23]  M. Ponec,et al.  Fresh versus cryopreserved cultured allografts for the treatment of chronic skin ulcers , 1990, The British journal of dermatology.

[24]  R. Kirsner,et al.  The biology of skin grafts. Skin grafts as pharmacologic agents. , 1993, Archives of dermatology.

[25]  D. Margolis,et al.  Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. , 1998, Archives of dermatology.

[26]  S. Gordon,et al.  Human skin equivalent in the treatment of chronic leg ulcers in sickle cell disease patients. , 2003, Journal of the American Podiatric Medical Association.

[27]  I. Leigh,et al.  Survival of cultured allogeneic keratinocytes transplanted to deep dermal bed assessed with probe specific for Y chromosome. , 1989, BMJ.

[28]  U. Saarialho-Kere,et al.  Differential expression of tissue inhibitors of metalloproteinases (TIMP-1, -2, -3, and -4) in normal and aberrant wound healing. , 1999, Human pathology.

[29]  V. Falanga,et al.  Wounding of bioengineered skin: cellular and molecular aspects after injury. , 2002, The Journal of investigative dermatology.

[30]  H Green,et al.  Treatment of skin ulcers with cultured epidermal allografts. , 1989, Journal of the American Academy of Dermatology.

[31]  H. Brem,et al.  Healing of Venous Ulcers of Long Duration with a Bilayered Living Skin Substitute: Results from a General Surgery and Dermatology Department , 2001, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[32]  R. Price,et al.  Survival of Apligraf in acute human wounds. , 2004, Tissue engineering.